Covered recipient · General Payments record
ELIZABETH I PLIMACK
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2018–2024
$212,595.51
- Reported across 186 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $19,457.50 | 9 |
| Food and Beverage | $205.13 | 5 |
| Travel and Lodging | $70.20 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| EISAI INC. | $6,335.23 | 4 |
| ABBVIE INC. | $3,490.60 | 2 |
| Merck Sharp & Dohme Corporation | $2,135.00 | 1 |
| AstraZeneca UK Limited | $2,055.00 | 1 |
| PFIZER INC. | $1,875.00 | 1 |
| E.R. Squibb & Sons, L.L.C. | $1,642.00 | 4 |
| Astellas Pharma Global Development | $1,250.00 | 1 |
| EMD Serono Research & Development Institute, Inc. | $950.00 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $115.60 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105280134 | CMS |
| ABBVIE INC. | $3,375.00 | 03/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105280138 | CMS |
| Astellas Pharma Global Development | $1,250.00 | 03/22/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1132966837 | CMS |
| AstraZeneca UK Limited | $2,055.00 | 01/11/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1093917426 | CMS |
| E.R. Squibb & Sons, L.L.C. | $26.95 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101363460 | CMS |
| E.R. Squibb & Sons, L.L.C. | $7.35 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101363532 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,537.50 | 07/08/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101363476 | CMS |
| E.R. Squibb & Sons, L.L.C. | $70.20 | 07/12/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1101363480 | CMS |
| Eisai Inc. | $1,962.50 | 03/27/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1110743633 | CMS |
| Eisai Inc. | $35.72 | 11/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110743629 | CMS |
| Eisai Inc. | $19.51 | 11/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110743631 | CMS |
| Eisai Inc. | $4,317.50 | 12/11/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1110743635 | CMS |
| EMD Serono Research & Development Institute, Inc. | $950.00 | 03/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1120275364 | CMS |
| Merck Sharp & Dohme LLC | $2,135.00 | 02/26/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141772506 | CMS |
| PFIZER INC. | $1,875.00 | 11/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1131374051 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.